Saliva soluble HLA as a potential marker of response to interferon-βIa in multiple sclerosis: A preliminary study

Journal of Neuroinflammation

Volumn 4, Issue , 2007, Pages

  Minagar, Alireza ^a   Adamashvili, Irena ^a   Kelley, Roger E ^a   Gonzalez Toledo, Eduardo ^a   McLarty, Jerry ^a   Smith, Stacy J ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; BETA INTERFERON; BIOLOGICAL MARKER; HLA ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; DRUG RESPONSE; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RECURRENT DISEASE; SALIVA LEVEL; BIOSYNTHESIS; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SALIVA;

ADULT; BIOLOGICAL MARKERS; FEMALE; HLA ANTIGENS; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SALIVA;

EID: 34547819812     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-4-16     Document Type: Article

References (30)

1. Aultman D Adamashvili I Yaturu K Gelder F McDonald J Soluble HLA in human body fluids Hum Immunol 1999 60 239-244 10.1016/ S0198-8859(98)00122-0 10321960
2. Calne R Sells R Pena J Davis P Induction of immunological tolerance by porcine liver allografts Nature 1969 223 472-476 10.1038/223472a0 4894426
3. Davies H Pollard S Calne R Soluble HLA antigens in the circulation of liver graft recipients Transplantation 1989 47 524-527 2646783
4. Lindaan A Dowden A Zavazava N Soluble HLA-G molecules induce apoptosis in natural killer cells Am J Reprod Immunol 2006 56 68-76 10.1111/ j.1600-0897.2006.00395.x 16792533
5. Adamashvili I McDonald J Fraser P Milford E Pressly T Gelder F Soluble class I HLA antigens in patients with rheumatoid arthritis and their families J Rheumatol 1995 22 1025-1031 7674225
6. Adamashvili I McVie R Gelder F Gautreaux M McDonald J Soluble HLA class I antigens in patients with type I diabetes and their family members Hum Immunol 1997 55 176-183 10.1016/S0198-8859(97)00096-7 9361970
7. Adamashvili I Wolf R Milford E Pressly T Minagar A Kelley R Soluble HLA-I synthesis in systemic lupus erythematosus Rheumatol Int 2003 23 294-300 10.1007/s00296-003-0306-3 12879264
8. Tabayoyong WB Zavazava N Soluble HLA revisited Leuk Res 2006 31 121-125 10.1016/j.leukres.2006.06.008 16860865
9. McDonald J Adamashvili I Hayes M Aultman D Rhynes K Gelder F Soluble HLA-class II concentrations in normal individuals and transplant recipients: Comparison to soluble HLA-class I concentrations Transplantation 1994 58 1268-1272 10.1097/00007890-199412270-00023 7992373
10. Hayman M van Beijnen MT Stamp LK Spellerberg MB O'Donnell JL Soluble human leukocyte antigen: A diagnostic indicator of rheumatoid arthritis? J Immunol Methods 2006 315 19-26 10.1016/j.jim.2006.06.013 16893550
11. Adamashvili I Pressly T Wolf R Hall V McDonald J Soluble HLA in saliva of patients with autoimmune rheumatic diseases: Rheumatol Int Rheumatol Int 2002 22 71-76 10.1007/s00296-002-0173-3 12070679
12. Ott M Seidl C Westhoff U Stecker K Seifried E Fischer P Grosse-Wilde H Soluble HLA class I and class II antigens in patients with multiple sclerosis Tissue Antigens 1998 51 301-314 9550332
13. Alvarez-Cermeno J Villar L Nocito M Bootello A Gonzalez-Porque P Intrathecal synthesis of soluble class I antigens in multiple sclerosis J Neuroimmunology 1992 36 1 77-79 10.1016/0165-5728(92)90032-G
14. Filaci G Contini P Brenci S Gazzola P Lanza L Scudeletti M Indiveri F Mancardi GL Puppo F Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients Hum Immunol 1997 54 54-62 10.1016/S0198-8859(97)00004-9 9154458
15. Fainardi E Rizzo R Melchiorri L Castellazzi M Govoni V Caniatti L Paolino E Tola MR Granieri E Baricordi OR Beneficial effect of interferon-beta1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy J Neuroimmunol 2004 148 206-211 10.1016/j.jneuroim.2003.12.002 14975603
16. Adamashvili I Minagar A Gonzales-Toledo E Featherston L Kelley R Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: A preliminary study J Neuroinflammation 2005 2 13-16 1180848 15932635 10.1186/1742-2094-2-13
17. McDonald WI Compston A Edan G Goodkin D Hartung HP Lublin FD McFarland HF Paty DW Polman CH Reingold SC Sandberg-Wollheim M Sibley W Thompson A van den Noort S Weinshenker BY Wolinsky JS Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis Ann Neurol 2002 50 121-127 10.1002/ana.1032
18. Adamashvili I Fraser P Milford E Sittig K Gebel H Zibari G Pressly T McDonald J Soluble HLA expression in African-Americans Inflamm Res 2002 51 290-294 10.1007/PL00000306 12088269
19. Friedman M The use of ranks to avoid the assumption of normality implicit in the analysis of variance J Amer Statist Assoc 1937 32 675-701 10.2307/2279372
20. Stone LA Frank JA Albert PS Bash CN Calabresi PA Maloni H McFarland HF Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure Neurology 1997 49 862-869 9305355
21. Waubant E Vukusic S Gignoux L Dubief FD Achiti I Blanc S Renoux C Confavreux C Clinical characteristics of responders to interferon therapy for relapsing MS Neurology 2003 61 184-189 10.1159/000070702 12874396
22. Sorensen PS Ross C Clemmesen KM Bendtzen K Frederiksen JL Jensen K Kristensen O Petersen T Rasmussen S Ravnborg M Stenager E Koch-Henriksen N Danish Multiple Sclerosis Study Group Clinical importance of neutralizing antibodies against interferon beta in relapsing-remitting multiple sclerosis Lancet 2003 362 1184-1191 10.1016/ S0140-6736(03)14541-2 14568740
23. Chadha K Winstock-Guttman B Zivadinov R Bhasi K Muhitch J Feichter J Tamano-Blanco M Abdelrahman N Ambrus J Sr Munschauer F Ramanathan M Interferon inhibitory activity in patients with multiple sclerosis Arch Neurol 2006 63 1579-1584 10.1001/archneur.63.11.1579 17101826
24. Langer-Gould A Popat RA Huang SM Cobb K Fontoura P Gould MK Nelson LM Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis Arch Neurol 2006 63 1686-1691 10.1001/archneur.63.12.1686 17172607
25. Colucci M Roccatagliata L Capello E Narciso E Latronico N Tabaton M Mancardi GL The 14-3-3 protein in multiple sclerosis: A marker of disease severity Mult Scler 2004 10 477-481 10.1191/1352458504ms1089oa 15471360
26. Niino M Bodner C Simard ML Alatab S Gano D Kim HJ Trigueiro M Racicot D Guerette C Antel JP Fournier A Grand'Maison F Bar-Or A Natalizumab effects on immune cell responses in multiple sclerosis Ann Neurol 2006 59 748-754 10.1002/ana.20859 16634035
27. Pollard S Davies HFFS Calne R Perioperative appearance of serum class I antigen during liver transplantation Transplantation 1990 49 659-663 10.1097/00007890-199003000-00039 2316027
28. Stevenson FK Georg AJ Walters MT Hamblin TJ Analysis of soluble HLA class II antigenic material in patients with immunological diseases using monoclonal antibodies J Immunol Methods 1986 86 187-190 10.1016/ 0022-1759(86)90451-5 2418122
29. Minagar A Adamashvili I Jaffe SL Glabus M Gonzales-Toledo E Kelley RE Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: Acute response to interferon-(beta) 1a treatment and their use as markers of disease activity Ann N Y Acad Sci 2005 1005 111-120 10.1196/annals.1361.052
30. Mitsdoerffer M Schreiner B Kieseier BC Neuhaus O Dichgans J Hartung HP Weller M Wiendl H Monocyte-derived HLA-G acts as a strong inhibitor of Autologous CD4 T cell activation and is unregulated by interferon-beta in vitro and In vivo: Rationale for the therapy of multiple sclerosis J Neuroimmunol 2005 159 155-164 10.1016/j.jneuroim.2004.09.016 15652415